BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME	POSITION TITLE
Elaine R. Peskind, MD	Professor
eRA COMMONS USER NAME (credential, e.g., agency login) epeskind	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	MM/YY	FIELD OF STUDY
California State College, San Bernadino, CA	BS with high honors	1975	Biology
Washington State University, Pullman, WA	MS	1978	Zoology
University of Washington, Seattle, WA	MD with honors	1986	Medicine
University of Washington, Seattle, WA	Resident	1990	Psychiatry
VA Puget Sound Health Care System, Seattle, WA	Fellow	1991	Geriatric Psychiatry

A. Personal Statement

I am the Friends of Alzheimer's Research Professor of Psychiatry in the Dept. of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine. I have over 25 years of experience in research in as well as clinical evaluation and management of neurodegenerative dementing disorders of aging, with a particular focus on cerebrospinal fluid (CSF) collection for research purposes and development of CSF biomarkers. As Associate Director of the UW ADRC, Director of the Clinical Core and Director of the UW ADRC CSF repository, I am able to provide CSF samples, as well as DNA samples, and appropriate clinical data from well clinically characterized patients with MCI and AD, as well as a large number of normal controls across the adult lifespan (ages 21-101). I have pioneered methods for safe and acceptable CSF collection for research purposes and have served as PI of my own National Alzheimer's Coordinating Center-funded study of the relationship of APOE genotype and CSF neurohormones and have collaborated widely to provide CSF samples for studies of CSF and plasma biomarkers, including proteomics studies. All of our CSF samples are collected under very well controlled conditions: 1) collected between 9:00 am - 11:00 am after overnight fasting; 2) collected with the Sprotte 25g atraumatic spinal needle; 3) aliquoted and frozen on dry ice at the bedside; 4) no contact with non-polypropylene collection and storage materials; and 5) maintained frozen in -80° freezers without freeze/thaw. My own work on CSF biomarkers as well as my collaborative research relationships have led to important progress in establishing a preclinical state of incipient AD that may be between 1-2 decades as well as proteomics of nearly 3,000 proteins in CSF, a discovery which may provide useful tools for early diagnosis or disease and monitored therapeutic response, identification of individuals with preclinical disease for our ultimate goal of primary prevention. In the Clinical Core of the ADRC, we have had a very high accuracy rate for clinical diagnosis of AD – with a rate of clinically diagnosed AD confirmed on autopsy of 97% for the past ten years.

B. Positions and Honors

Positions and Employment

1991-1994 Attending Psychiatrist, University of Washington (UW) Medical Center, UW, Seattle, WA
1991-1996 Assistant Professor, Dept of Psychiatry and Behavioral Sciences, UW School of Medicine, Seattle, WA
1994-1997 Staff Psychiatrist, VA Puget Sound Health Care System (VAPSHCS), Seattle, WA
1995-present Director of Clinical Research for Mental Health Service, VAPSHCS, Seattle, WA
1996-2000 Associate Professor, Dept of Psychiatry and Behavioral Sciences, UW School of Medicine, Seattle, WA
1997-present Co-Director, Mental Illness Research, Education and Clinical Center (MIRECC), Northwest Network, Seattle, WA

2000-present Professor, Dept of Psychiatry and Behavioral Sciences, UW School of Medicine, Seattle, WA
2002-present Associate Director, UW Alzheimer's Disease Research Center, Seattle, WA
2009-present Friends of Alzheimer's Research Professor of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA

Honors and Awards

1975 Graduation with High Honors, California State College, San Bernadino
1984 Herbert S. Ripley Psychiatry Research Thesis Award, UW School of Medicine
1985 Alpha Omega Alpha, elected Junior year
1985 Rock Sleyster Scholar, American Medical Association
1986 Graduation with Honors, UW School of Medicine
1986 Margaret H. O'Donnell Prize in Psychiatry, UW School of Medicine
1986 Janet M. Glasgow Memorial Achievement Citation of the American Medical Women's Assoc.
7/89-6/91 Research Training for Veterans Administration Psychiatrists Award
7/90-6/91 Thomas H. Holmes Research Scholar Award
1990 Director's Award, Department of Psychiatry and Behavioral Sciences, UW School of Medicine
1990 American College of Neuropsychopharmacology-Mead Johnson Travel Award
1996 Elected Member, American College of Neuropsychopharmacology
1997-2001 National Institute on Aging Neuroscience of Aging Review Committee
2002- National Institute on Aging Alzheimer's Disease Centers Clinical Task Force
2003 National Institute on Aging Special Emphasis Panel, Alzheimer's Disease Research Centers
2006-2007 NIA/NIH Alzheimer's Disease Centers BiospecimenTask Force: Best Practice Guidelines
2009 Lasting Memory Award, Alzheimer's Association

C. Selected Peer-Reviewed Publications (selected from over 200).

1. Peskind ER, Wilkinson CW, Petrie E, Schellenberg G, Raskind MA. Increased CSF cortisol in Alzheimer's disease is a function of apolipoprotein E genotype. Neurology 56:1094-1098, 2001.
2. Zhang J, Goodlett DR, Peskind ER, Quinn JF, Zhou Y, Pan C, Yi E, Eng J, Aebersold RH, Montine TJ. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 26:207-227, 2005
3. Peskind ER, Riekse R, Quinn JF, Kaye J, Clark CM, Farlow MR, Decarli C, Chabal C, Vavrek D, Raskind MA, Galasko D. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 19:220-5, 2005.
4. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, Aebersold RH, Montine TJ. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer's disease. J Alz Dis 7:125-133, 2005.
5. Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 63:936-9, 2006.
6. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9:293-348, 2006.
7. Pan S, Wang Y, Quinn JF, Peskind ER, Waichunas D, Wimberger JT, Jin J, Li JG, Zhu D, Pan C, Zhang J. Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. J Proteome Res 5:2769-79, 2006.
8. Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, Rosenthal E, Wijsman EM, Tsuang DW, Devlin B, Schellenberg GD. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics 89:655-65, 2007.
9. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology;69:631-9, 2007.
10. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind E, Raskind MA, Breitner JCS, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer's disease. Neurology 69:878-885, 2007.

11. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ.CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008 Apr;129(4):526-9.PMID: 18343778
12. Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, Jankovic J, Leverenz JB, Zabetian C, Pan C, Wang Y, Oh JH, Gao J, Zhang J, Montine T, Zhang J. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008 Feb;7(2):720-30. Epub 2008 Jan 11.PMID: 18186601
13. Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, Jankovic J, Su Z, Hancock AM, Pan C, Montine TJ, Pan S, Nutt J, Albin R, Gearing M, Beyer RP, Shi M, Zhang J. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev 2009 Apr 8 [Epub ahead of print] PMID 19358229
14. Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S. Preclinical evidence of Alzheimer's changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol 2009 66(5):632-7. PMID 19433663
15. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci USA 2009 106(29):12145-50. PMID 19581601

D. Research Support

NIH/NIA - R01 AG033133 - Peskind (PI) - 8/15/09-7/31/12
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
The primary goal of this proposal is to undertake a placebo-controlled pilot trial of the generically available brain active alpha-1 adrenoreceptor antagonist, prazosin, for disruptive agitation in AD. Role: PI

NIH/NIA - P50 AG05136 - Raskind (PI) - 5/1/05-4/30/10
Alzheimer's Disease Research Center - Core C – Clinical - (Peskind PI)
The major goals of the Clinical Core are 1) to characterize and regularly evaluate patients with Alzheimer's disease for ADRC research projects and 2) to characterize and regularly evaluate age-matched normal control subjects for ADRC research projects. Role: PI of Clinical Core

Department of Veterans Affairs - Prazosin and Combat Trauma PTSD (PACT) - (Peskind/Raskind) - 10/1/07-9/30/12
VA Cooperative Studies Program
The primary goal of this proposal is to evaluate the short-term efficacy and long-term effectiveness as well as tolerability of prazosin for trauma nightmares, sleep disturbance, and global clinical status (sense of well-being and ability to function) in veterans with war zone trauma PTSD. We also will assess the effects of prazosin on total PTSD symptoms, depression, quality of life, and alcohol craving. Role: Co-PI

NIH/NIA - R01 AG033693 - Li (PI) - 8/15/09-7/31/12
Effects of Simvastatin on CSF AD Biomarkers in Cognitively Normal Subjects
The primary goal of this proposal is to undertake a 1-year fixed dose, randomized, placebo-controlled trial to evaluate the effects of simvastatin vs. placebo on CSF AD biomarkers in middle-aged and older (45–75 years) cognitively normal subjects who have a family history of AD. Role: Investigator

Department of Defense - A Placebo-Controlled Augmentation Trial of Prazosin for Combat Trauma PTSD (PT074250 Raskind) - 6/1/08-5/31/12
The goal of this study is to accelerate the generation of data addressing prazosin efficacy in a large placebo-controlled trial in OIF/OEF returnees to guide evidence-based practice. To accomplish this goal, a 2-arm prazosin vs. placebo augmentation trial in OIF/OEF returnees with PTSD and persistent trauma-related nightmares and sleep disruption will be performed. Role: Investigator

NIH/NINDS - R01 NS057567 - Zhang (PI) - 7/01/08-5/31/13
Biomarkers for Preclinical Parkinson's Disease
The major goal of this project is to identify protein biomarkers for preclinical PD in cerebrospinal fluid (CSF) and plasma. A high throughput proteomic approach will be used to screen for biomarkers in a nonhuman

primate PD model, followed by validation of putative markers in patients with sporadic and familial PD.
Role: Investigator